首页> 外文OA文献 >Zika Virus Envelope Domain III Recombinant Protein Delivered With Saponin-Based Nanoadjuvant From Quillaja brasiliensis Enhances Anti-Zika Immune Responses, Including Neutralizing Antibodies and Splenocyte Proliferation
【2h】

Zika Virus Envelope Domain III Recombinant Protein Delivered With Saponin-Based Nanoadjuvant From Quillaja brasiliensis Enhances Anti-Zika Immune Responses, Including Neutralizing Antibodies and Splenocyte Proliferation

机译:Zika病毒包络域III从Quillaja Brasiliensis用皂苷的纳米载物递送的重组蛋白增强了抗Zika免疫应答,包括中和抗体和脾细胞增殖

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nanoadjuvants that combine immunostimulatory properties and delivery systems reportedly bestow major improvements on the efficacy of recombinant, protein-based vaccines. Among these, self-assembled micellar formulations named ISCOMs (immune stimulating complexes) show a great ability to trigger powerful immunological responses against infectious pathogens. Here, a nanoadjuvant preparation, based on saponins from Quillaja brasiliensis, was evaluated together with an experimental Zika virus (ZIKV) vaccine (IQB80-zEDIII) and compared to an equivalent vaccine with alum as the standard adjuvant. The preparations were administered to mice in two doses (on days zero and 14) and immune responses were evaluated on day 28 post-priming. Serum levels of anti-Zika virus IgG, IgG1, IgG2b, IgG2c, IgG3 were significantly increased by the nanoadjuvant vaccine, compared to the mice that received the alum-adjuvanted vaccine or the unadjuvanted vaccine. In addition, a robust production of neutralizing antibodies and in vitro splenocyte proliferative responses were observed in mice immunized with IQB80-zEDIII nanoformulated vaccine. Therefore, the IQB80-zEDIII recombinant preparation seems to be a suitable candidate vaccine for ZIKV. Overall, this study identified saponin-based delivery systems as an adequate adjuvant for recombinant ZIKV vaccines and has important implications for recombinant protein-based vaccine formulations against other flaviviruses and possibly enveloped viruses.
机译:据报道,结合免疫刺激性能和递送系统的纳米乌纳乌纳欧瓦夫对重组,蛋白质疫苗的疗效进行了重大改进。其中,名为Iscoms(免疫刺激复合物)的自组装胶束制剂表现出强大引发强大免疫应答的能力。这里,基于来自Quillaja Brasiliensis的皂苷的纳米轴制剂与实验Zika病毒(Zikv)疫苗(IQB80-ZEDIII)一起评估,并与作为标准佐剂的等效疫苗进行比较。将制剂施用于两次剂量(在数天零和14天)中,并在灌注后第28天评估免疫应答。与接受明矾辅助疫苗或未破坏的疫苗的小鼠相比,纳米载荷疫苗显着增加血清抗Zika病毒IgG,IgG1,IgG2B,IgG2C,IgG3,IgG3显着增加。此外,在用IQB80- Zediii纳米型疫苗免疫的小鼠中观察到稳健的中和抗体和体外脾细胞增殖反应。因此,IQB80- ZediII重组制剂似乎是ZIKV的合适候选疫苗。总体而言,本研究确定了基于皂苷类的递送系统,作为重组ZIKV疫苗的适当佐剂,对重组蛋白质的疫苗制剂具有重要意义,对抗其他黄病毒和可能包膜病毒。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号